---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041299"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:32:42.928465+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Erasca Q2 2023 net loss $31.8M; cash $365.3M, funding into H2 2025

## Summary
- Net loss of $31.8M ($0.21/ share) vs $35.6M ($0.30) in Q2 2022; R&D spend $26.2M.
- Cash, equivalents, and marketable securities $365.3M as of Jun 30, 2023, down from $435.6M at Dec 31, 2022.
- ERAS-007 Phase 1b in BRAFm CRC showed 50% (3/6) response rate; expansion data expected H2 2023–H1 2024.
- First patient dosing in SEACRAFT-1 (naporafenib + trametinib) for RAS Q61X tumors expected H2 2023.
- FDA granted Fast Track and Orphan Drug Designations for ERAS-801 in recurrent glioblastoma.

## SEC filing metadata
- accession: 0000950170-23-041299
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/0000950170-23-041299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/eras-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041299
- JSON: https://secwatch.observer/filing/0000950170-23-041299.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041299.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported quarter ended June 30, 2023 results: net income Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023, EPS $(0.21).
  - Period: quarter ended June 30, 2023
  - Net income: Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023
  - EPS: $(0.21)
  - Result: reported results
  source text: Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/0000950170-23-041299-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.